The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.

•Members of the CD155/TIGIT immune checkpoint pathway are commonly expressed in HGSC and other cancers.•In HGSC, expression of CD155 and TIGIT is substantially more frequent than expression of PD-L1 and PD-1.•In contrast to PD-L1, CD155 is commonly expressed by immunologically cold tumors.•CD155 and PD-L1 appear to represent non-redundant immune checkpoints in HGSC.